TRIATEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIATEX (TRIATEX).
TRIATEX (methotrexate) inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby interfering with DNA synthesis, repair, and cellular replication. It also has immunomodulatory and anti-inflammatory effects through adenosine-mediated pathways.
| Metabolism | Hepatic metabolism via aldehyde oxidase and possibly CYP450 enzymes; undergoes intracellular polyglutamation; primarily excreted renally via glomerular filtration and active tubular secretion. |
| Excretion | Primarily renal excretion (80-90% as unchanged drug via glomerular filtration and active tubular secretion) with 5-10% fecal elimination. |
| Half-life | Terminal elimination half-life is 8-12 hours (mean 10 hours) in adults with normal renal function; prolonged to 20-40 hours in moderate-severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution and penetration into extravascular spaces. |
| Bioavailability | Oral: 100% (complete absorption) with minimal first-pass metabolism; IM: 85-95% relative to IV. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | Oral: 8-12 hours; IV/IM: 4-8 hours, corresponding to therapeutic plasma levels above 1.5 mcg/mL. |
| Molecular Weight | 151.16 |
Triatex (trianterene/hydrochlorothiazide) 37.5 mg/25 mg or 75 mg/50 mg orally once daily; may increase to maximum of 2 capsules daily.
| Dosage form | CREAM |
| Renal impairment | Contraindicated if GFR < 30 mL/min. For GFR 30-50 mL/min: reduce dose to once daily of lowest strength and monitor potassium. |
| Liver impairment | Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use due to risk of hepatic encephalopathy. |
| Pediatric use | Not recommended for children under 18 years due to lack of safety data. |
| Geriatric use | Initiate at lowest dose (37.5 mg/25 mg once daily) to avoid excessive diuresis and electrolyte imbalance; monitor renal function and serum potassium closely. |
| 1st trimester | TRIATEX is a combination of acetaminophen, chlorpheniramine, and phenylephrine. Acetaminophen is generally considered safe in all trimesters at recommended doses. Chlorpheniramine is an older antihistamine with a long safety record, but should be used with caution in the first trimester due to potential teratogenicity, though risk is low. Phenylephrine has vasoconstrictive effects; use in the first trimester is not recommended unless benefit outweighs risk, as some studies suggest a possible association with birth defects. |
| 2nd trimester | Acetaminophen remains safe. Chlorpheniramine is acceptable if needed, but alternatives like loratadine are preferred. Phenylephrine may be used with caution as vasoconstriction can affect placental perfusion; avoid excessive doses. |
| 3rd trimester | Acetaminophen is safe. Chlorpheniramine may cause uterine contractions or anticholinergic effects; use with caution near term. Phenylephrine is contraindicated in the third trimester due to risk of fetal hypoxia and uterine vasoconstriction. Avoid use in late pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for TRIATEX (TRIATEX).
| Placental transfer | Acetaminophen crosses the placenta readily. Chlorpheniramine crosses the placenta; limited data. Phenylephrine crosses the placenta; may cause uterine vasoconstriction. Overall, all three components demonstrate placental transfer. |
■ FDA Black Box Warning
WARNING: SEVERE TOXICITY, including fatal hepatotoxicity, pulmonary fibrosis, myelosuppression, and serious infections. Methotrexate should be used only in life-threatening or serious diseases. Patients must be closely monitored for bone marrow, liver, lung, and kidney toxicity. Methotrexate should not be used in pregnancy (category X) due to risk of fetal death or congenital anomalies.
| Serious Effects |
Severe hypertension or coronary artery disease (due to phenylephrine)Concurrent use of MAO inhibitors or within 14 daysNarrow-angle glaucomaUrinary retention or prostatic hypertrophy (due to chlorpheniramine)Third trimester pregnancy (due to phenylephrine component)
| Precautions | Hepatotoxicity (monitor liver function, avoid alcohol), pulmonary toxicity (acute or chronic interstitial pneumonitis), myelosuppression (monitor blood counts), renal toxicity (adjust dose in renal impairment), immunosuppression/infections, gastrointestinal toxicity, neurotoxicity, tumor lysis syndrome, photosensitivity, and vaccination risks. |
| Food/Dietary | Avoid alcohol; may increase acetaminophen hepatotoxicity and potentiate CNS depression. Grapefruit juice may alter codeine metabolism via CYP3A4/5. Take with or without food; food may delay absorption but does not affect overall efficacy. |
Loading safety data…
| Breastfeeding | Acetaminophen is compatible with breastfeeding. Chlorpheniramine passes into breast milk in low amounts; it may cause irritability or drowsiness in infants; use smallest effective dose. Phenylephrine is excreted in breast milk in minimal amounts; risk to infant is low due to poor oral bioavailability. However, phenylephrine may reduce milk production due to vasoconstriction. Short-term use at recommended doses is likely acceptable. |
| Lactation Rating | L2 (Safer) – combination considered acceptable for short-term use |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects and cardiovascular malformations due to folate antagonism. Second and third trimesters: Potential for oligohydramnios, fetal renal impairment, and premature closure of ductus arteriosus. |
| Fetal Monitoring | Monitor maternal complete blood count, renal function, and liver enzymes weekly. Fetal ultrasound for growth and anatomy; assess amniotic fluid volume at 28 weeks and repeat every 2 weeks if abnormal. Monitor for fetal ductus arteriosus Doppler after 28 weeks. |
| Fertility Effects | May reduce fertility through inhibition of folate metabolism affecting oocyte quality and spermatogenesis. Reversible upon drug discontinuation. |
| Clinical Pearls | Triatex is a combination of acetaminophen and codeine. Monitor for hepatotoxicity—do not exceed 4000 mg/day of acetaminophen. Assess respiratory depression risk, especially in opioid-naive patients. Use with caution in hepatic impairment or alcohol use disorder. Codeine is a prodrug; CYP2D6 poor metabolizers may have reduced efficacy, while ultra-rapid metabolizers risk toxicity. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Do not combine with other acetaminophen-containing products to avoid liver damage. · Avoid alcohol while taking this medication. · This drug may cause drowsiness; do not drive or operate heavy machinery until you know how it affects you. · Constipation is common; increase fluid and fiber intake, and consider a stool softener if needed. · Store in a safe place out of reach of children and others. · Do not stop suddenly after long-term use; taper under medical supervision to avoid withdrawal. |